Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3215-3219

  Grieu, Fabienne ^a   Powell, Brenda ^b   Beilby, John ^a   Iacopetta, Barry ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Breast cancer; Folate; MTHFR; Polymorphism; TS

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA METHYLATION; DNA POLYMORPHISM; DNA REPAIR; ENHANCER REGION; FOLATE METABOLISM; GENE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TANDEM REPEAT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; THYMIDYLATE SYNTHASE;

EID: 6344254633     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Choi SW and Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr 130: 129-132, 2000.
2. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, Colditz GA, Speizer FE and Willett WC: A prospective study of folate intake and the risk of breast cancer. JAMA 281: 1632-1637, 1999.
3. Beilby J, Ingram D, Hahnel R and Rossi E: Reduced breast cancer risk with increasing serum folate in a case-control study of the C677T genotype of the methylenetetrahydrofolate reductase gene. Eur J Cancer 40: 1250-1254, 2004.
4. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB and Ames BN: Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 94: 3290-3295, 1997.
5. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
7. Stern LL, Mason JB, Selhub J and Choi SW: Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 9: 849-853, 2000.
8. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G and Iacopetta B: The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 9: 5860-5865, 2003.
9. Horie N, Aiba H, Oguro K, Hojo H and Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20: 191-197, 1995.
10. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19(4B): 3249-3252, 1999.
11. Chen J, Hunter DJ, Stampfer MJ, Kyte C, Chan W, Wetmur JG, Mosig R, Selhub J and Ma J: Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 12: 958-962, 2003.
12. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, Rollinson S, Roman E, Cartwright RA and Morgan GJ: Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 99: 3786-3791, 2002.
13. Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kadouri E and Friedman E: Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 36: 2313-2316, 2000.
14. Sharp L, Little J, Schofield AC, Pavlidou E, Cotton SC, Miedzybrodzka Z, Baird JO, Haites NE, Heys SD and Grubb DA: Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 181: 65-71, 2002.
15. Campbell IG, Baxter SW, Eccles DM and Choong DY: Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 4(6): R14, 2002.
16. Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Weitzer W and Samonigg H: The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat 81: 169-172, 2003.
17. Semenza JC, Delfino RJ, Ziogas A and Anton-Culver H: Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. Breast Cancer Res Treat 77: 217-223, 2003.
18. Ergul E, Sazci A, Utkan Z and Canturk NZ: Polymorphisms in the MTHFR gene are associated with breast cancer. Tumour Biol 24: 286-290, 2003.
19. Shrubsole MJ, Gao YT, Cai Q, Shu XO, Dai Q, Hebert JR, Jin F and Zheng W: MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 13: 190-196, 2004.
20. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM and Iacopetta B: Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 23: 311-315, 2002.
21. Powell BL, Piersma D, Kevenaar ME, van Staveren IL, Themmen AP, Iacopetta BJ and Berns EM: Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. J Clin Endocrinol Metab 88: 1653-1657, 2003.
22. Iacopetta B, Grieu F and Joseph D: The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotye. Br J Cancer 90: 419-422, 2004.
23. Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R and Robbins PD: Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74: 642-647, 1997.
24. Grieu F, Joseph D, Norman P and Iacopetta B: Development of a rapid genotyping method for single nucleotide polymorphisms and its application in cancer studies. Oncol Rep 11: 501-504, 2004.
25. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA and Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8: 843-854, 1999.
26. Grieu F, Malaney S, Ward R, Joseph D and Iacopetta B: Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23: 4257-4259, 2003.
27. Sohn KJ, Croxford R, Yates Z, Lucock M and Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96: 134-144, 2004.
28. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G and Rozen R: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9: 1611-1615, 2003.
29. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S and Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70, 2001.
30. Toffoli G, Veronesi A, Boiocchi M and Crivellari D: MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 11: 373-374, 2000.